Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Operations (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Cash from Operations for 4 consecutive years, with 55807000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 30.39% to 55807000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 193817000.0 through Dec 2025, down 36.44% year-over-year, with the annual reading at 193817000.0 for FY2025, 36.44% down from the prior year.
  • Cash from Operations for Q4 2025 was 55807000.0 at Centessa Pharmaceuticals, up from 58312000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 21389000.0 in Q3 2024, with the low at 59877000.0 in Q2 2022.
  • Average Cash from Operations over 4 years is 43547500.0, with a median of 43431000.0 recorded in 2023.
  • Peak annual rise in Cash from Operations hit 44.67% in 2025, while the deepest fall reached 172.63% in 2025.
  • Over 4 years, Cash from Operations stood at 51564000.0 in 2022, then skyrocketed by 39.78% to 31050000.0 in 2023, then tumbled by 37.84% to 42800000.0 in 2024, then plummeted by 30.39% to 55807000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 55807000.0, 58312000.0, and 22452000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.